NSCLC Stage IIIB Clinical Trial
Official title:
Exploratory Study Evaluating the Potential of Immune Signature Profiling for Predicting Response in Patients With Resectable Stage II, IIIA and Select IIIB (T3N2 Only) Non-squamous Non-Small Cell Lung Cancer (NSCLC) to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to neoadjuvant ATEZOLIZUMAB plus Carboplatin/nab Paclitaxel Atezolizumab is given as intravenous infusion at a fixed dose of 1200 mg, day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase, Carboplatin at an initial dose of AUC (area under curve) 5 mg/mL/min, intravenously day 1 of each 21-day cycle for 3 cycles during the neoadjuvant treatment Phase, and Nab-Paclitaxel (Abraxane) at 100 mg/m2, intravenously day 1, 8 and 15 of each 21-day cycle for 3 cycles during the neoadjuvant treatment phase. Surgery after the 3rd cycle Atezolizumab / Carboplatin / Nab-Paclitaxel is standard procedure.
In early stages of non-small cell lung cancer (NSCLC), surgical treatment with curative intent is the treatment of choice. Adjuvant chemotherapy is standard of care for fully resected stage II, IIIA, or select IIIB [T3N2] NSCLC to improve survival outcome as compared to surgery alone. Neoadjuvant platinum-based chemotherapy has become a widely accepted alternative therapy. Chemotherapy regimens used in the adjuvant and neoadjuvant settings consist of platinum-based doublets. With the successful development of cancer immunotherapy in advanced NSCLC, several (neo)adjuvant studies of anti-PD-1/PD-L1 inhibitors are currently being conducted in resectable early-stage NSCLC. The IREP study explores neoadjuvant immunochemotherapy with three cycles of atezolizumab, carboplatin and nab-paclitaxel in patients with histologically confirmed and resectable non-squamous NSCLC Stage II, IIIA or select IIIB (T3N2 only). The primary endpoint of the study is the Major Pathologic Response (MPR) rate (≤10% residual viable tumor cells) at surgery. Secondary endpoints include EFS and OS, safety endpoints as well as analyses of molecular and immunological biomarkers that are predictive of response to the neoadjuvant immunochemotherapy treatment. Atezolizumab is given as intravenous infusion at a fixed dose of 1200 mg day 1, carboplatin at an initial dose of AUC 5 mg/mL/min intravenously day 1 and nab-paclitaxel at 100 mg/m2 intravenously day 1, 8 and 15 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. Subsequent surgery is standard procedure with standard lobectomy / bi-lobectomy with systematic lymph node dissection. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04042558 -
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
|
Phase 2 | |
Recruiting |
NCT04467801 -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
|
Phase 2 | |
Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 | |
Recruiting |
NCT05281406 -
Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
|
Phase 2 | |
Active, not recruiting |
NCT04223596 -
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
|
Phase 2 | |
Not yet recruiting |
NCT06374160 -
Exercise in Patients With Advanced Non-small Cell Lung Cancer
|
N/A | |
Recruiting |
NCT05652868 -
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT00198432 -
Chemoradiotherapy of NSCLC Stage IIIB
|
Phase 2 | |
Terminated |
NCT03805841 -
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
|
Phase 2 | |
Withdrawn |
NCT05212922 -
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
|
Phase 2 | |
Active, not recruiting |
NCT04932343 -
Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
|
||
Withdrawn |
NCT03231475 -
Phase I Study of SPH1188-11 in NSCLC
|
Phase 1 | |
Withdrawn |
NCT03628144 -
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05816499 -
Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03620669 -
1st Line Durvalumab in PS 2 NSCLC Patients
|
Phase 2 | |
Not yet recruiting |
NCT03594682 -
Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration:A Real World Exploratory Study
|
N/A | |
Completed |
NCT03515252 -
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
|
Phase 1 |